N/A N=26 Health Services Research

Characterizing and Addressing Financial Toxicity in AYAs With Cancer

Cancer in Adolescence

Bottom Line

View on ClinicalTrials.gov: NCT06072833 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2026

Primary outcome: Primary: Number of Participants Who Completed the Intervention — 21 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Patient Financial Education / Navigation (Behavioral)
Age: Pediatric, Adult · 15+ yrs
Sex: All
Sponsor: Columbia University
Primary completion: Feb 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Completed the Intervention	21	—
PRIMARY Number of Eligible Participants Who Received the Intervention	23	—
SECONDARY Comprehensive Score of Financial Toxicity (COST Measure) Score	10.47; 16.53	—

Summary

The overall aims of this study are to address two important gaps in care for AYA cancer patients: 1) a financial toxicity measurement tool to assess AYA-specific needs, and 2) an intervention for mitigating financial toxicity in this population. Aim 1 involves adapting the COSTA measure and assessing the psychometric properties of the measure for a racial/ethnically diverse group of AYAs. Aim 2 and 3 involve the development and pilot testing of our novel financial education/ navigation (FE/FN) intervention.

Eligibility Criteria

Inclusion Criteria

AYA patient participants:

Age 15 - 39 years old
English or Spanish-speaking
Diagnosed with cancer that required treatment within past 18 months
Not currently on hospice care

Caregiver/financial partner participants:

Parent or financially-responsible adult of non-adult AYA (<18 years) OR
Identified by the AYA as caregiver, parent, or partner who is financially-responsible or a financial partner for AYA

Exclusion Criteria

Unable to complete financial survey questions or contraindicated (as outlined in Protection of Human Subjects)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06072833). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.